H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Rain Oncology to $19 from $12 and keeps a Buy rating on the shares. The company last month announced that the topline data from its Phase 3 trial of milademetan versus Yondelis in liposarcoma would be delayed by a quarter, with a primary endpoint readout now slated to occur in Q2, the analyst tells investors in a research note. The firm views this favorably, saying a delay in reaching the required number of progression-free survival events could indicate that the active arm is performing well assuming the control arm performs as expected.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on RAIN:
- Rain Oncology reports Q4 EPS (70c), consensus (56c)
- Rain Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress
- TipRanks ‘Perfect 10’ List: There’s an Opportunity Brewing in These 2 Stocks
- Rain Oncology delayed data could be positive sign, says JonesResearch
- Rain Oncology to Participate in the 2023 Citi Virtual Oncology Leadership Summit